To observe the efficiency for patient with stage II-III HR+/HER2+ early breast cancer with standard neoadjuvant therapy, a retrospective, multicenter study in real world settings.
This study collected patients used standard neoadjuvant therapy (TCbHP/THP/EC-THP/AC-THP) among stage II-III HR+/HER2+ early breast cancer, and to describe patient clinical characteristics and clinical outcomes of them in real world settings.
Study Type
OBSERVATIONAL
Enrollment
200
Standard Therapy, including TCbHP, THP, EC-THP, AC-THP
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China
RECRUITINGTotal pathological complete response (tpCR)
tpCR is defined as the absence of residual invasive cancer on resected breast specimen and the sampled regional lymph nodes as shown by hematoxylin-eosin staining after completion of the neoadjuvant treatment.
Time frame: through study completion, an average of 1 year
Best overall response rate (BORR) [ Time Frame: During neoadjuvant treatment
The proportion of patients who respond to the treatment at any study time point
Time frame: through study completion, an average of 1 year
Residual cancer burden (RCB)
RCB score is obtained according to pathological evaluation after completion of neoadjuvant treatment and surgery
Time frame: through study completion, an average of 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.